[HTML][HTML] Comparing efficacy of erlotinib and bevacizumab combination with erlotinib monotherapy in patients with advanced non-small cell lung cancer (NSCLC): A …
P Sakharkar, S Kurup - Diseases, 2023 - mdpi.com
The objective of this systematic review and meta-analysis was to assess and contrast the
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …
efficacy and safety of combining erlotinib and bevacizumab with erlotinib alone in the …
Erlotinib in combination with bevacizumab has potential benefit in non-small cell lung cancer: a systematic review and meta-analysis of randomized clinical trials
B Zhao, W Zhang, D Yu, J Xu, Y Wei - Lung Cancer, 2018 - Elsevier
Objectives A role for erlotinib and bevacizumab as single agents has been established in
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …
the treatment of non-small cell lung cancer (NSCLC). However, the efficacy and safety of …
[HTML][HTML] Efficacy and safety of erlotinib combined with bevacizumab in the treatment of non-small cell lung cancer: A systematic review and meta-analysis
K Zhou, S Zhao, W Guo, L Ding - Medicine, 2020 - journals.lww.com
Background: Non-small cell lung cancer (NSCLC) has a poor prognosis despite
conventional treatments of surgery, radiotherapy, and chemotherapy. Small-molecule …
conventional treatments of surgery, radiotherapy, and chemotherapy. Small-molecule …
[HTML][HTML] Chemotherapy plus erlotinib versus chemotherapy alone for treating advanced non-small cell lung cancer: a meta-analysis
JL Xu, B Jin, ZH Ren, YQ Lou, ZR Zhou, QZ Yang… - PloS one, 2015 - journals.plos.org
Background Whether a combination of chemotherapy and erlotinib is beneficial for
advanced non-small cell lung cancer (NSCLC) remains controversial. This study aimed to …
advanced non-small cell lung cancer (NSCLC) remains controversial. This study aimed to …
Efficacy and safety of bevacizumab plus erlotinib versus bevacizumab or erlotinib alone in the treatment of non-small-cell lung cancer: a systematic review and meta …
S Zhang, X Mao, H Wang, F Cai, J Xu - BMJ open, 2016 - bmjopen.bmj.com
Objectives Bevacizumab and erlotinib inhibit different tumour growth pathways, and both
exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). However …
exhibit beneficial effects in the treatment of non-small-cell lung cancer (NSCLC). However …
Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment …
L Sun, JT Ma, SL Zhang, HW Zou, CB Han - Medical Oncology, 2015 - Springer
The meta-analysis evaluated the efficacy and safety of chemotherapy or tyrosine kinase
inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors …
inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors …
[HTML][HTML] A phase II study of erlotinib in combination with bevacizumab versus chemotherapy plus bevacizumab in the first-line treatment of advanced non-squamous …
T Ciuleanu, CM Tsai, CJ Tsao, J Milanowski… - Lung Cancer, 2013 - Elsevier
Background Molecularly targeted agents for non-small cell lung cancer (NSCLC) can
provide similar efficacy to chemotherapy without chemotherapy-associated toxicities …
provide similar efficacy to chemotherapy without chemotherapy-associated toxicities …
Treatment on advanced NSCLC: platinum-based chemotherapy plus erlotinib or platinum-based chemotherapy alone? A systematic review and meta-analysis of …
We performed a systematic review and meta-analysis to assess the potential of erlotinib plus
platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced …
platinum-based chemotherapy relative to platinum-based chemotherapy alone for advanced …
[HTML][HTML] Erlotinib in patients with advanced non-small-cell lung cancer: a meta-analysis
H Gao, X Ding, D Wei, P Cheng, X Su… - … lung cancer research, 2012 - ncbi.nlm.nih.gov
Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine
kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …
kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer …
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-small-cell lung cancer: a systematic review and meta-analysis of …
W Deng, K Wang, Y Jiang, D Li, C Bao, J Luo, L Liu… - BMJ open, 2022 - bmjopen.bmj.com
Objectives Combination treatment with erlotinib plus bevacizumab has the potential to
become a standard treatment regimen for patients with epidermal growth factor receptor …
become a standard treatment regimen for patients with epidermal growth factor receptor …